Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Two-Dimensional Liquid Chromatography Coupled to High-Resolution Mass Spectrometry for the Analysis of ADCs.

Chapel S, Rouvière F, Sarrut M, Heinisch S.

Methods Mol Biol. 2020;2078:163-185. doi: 10.1007/978-1-4939-9929-3_11.

PMID:
31643056
2.

Cabozantinib exposure-response analyses of efficacy and safety in patients with advanced hepatocellular carcinoma.

Nguyen L, Chapel S, Tran BD, Lacy S.

J Pharmacokinet Pharmacodyn. 2019 Oct 21. doi: 10.1007/s10928-019-09659-y. [Epub ahead of print]

PMID:
31637577
3.

Updated Population Pharmacokinetic Model of Cabozantinib Integrating Various Cancer Types Including Hepatocellular Carcinoma.

Nguyen L, Chapel S, Tran BD, Lacy S.

J Clin Pharmacol. 2019 Nov;59(11):1551-1561. doi: 10.1002/jcph.1467. Epub 2019 Jun 11.

4.

Population Pharmacokinetics of Pregabalin Extended-Release in Healthy Volunteers and Patients With Postherpetic Neuralgia, Fibromyalgia, and Partial-Onset Seizures.

Chew M, Ma G, Xie R, Bockbrader H, Chapel S, Marshall S.

J Clin Pharmacol. 2019 Nov;59(11):1527-1542. doi: 10.1002/jcph.1450. Epub 2019 Jun 11.

PMID:
31183879
5.

Clinical Pharmacokinetics and Pharmacodynamics of Dalcetrapib.

Black DM, Bentley D, Chapel S, Lee J, Briggs E, Heinonen T.

Clin Pharmacokinet. 2018 Nov;57(11):1359-1367. doi: 10.1007/s40262-018-0656-3. Review.

6.

Matthew Hutmacher, MS (1969-2017).

Chapel S, Kowalski KG.

CPT Pharmacometrics Syst Pharmacol. 2017 Aug;6(8):491. doi: 10.1002/psp4.12215. No abstract available.

7.

Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years.

Luo M, Chapel S, Sevinsky H, Savant I, Cirincione B, Bertz R, Roy A.

Antimicrob Agents Chemother. 2016 May 23;60(6):3676-86. doi: 10.1128/AAC.02678-15. Print 2016 Jun.

8.

Lurasidone Dose Response in Bipolar Depression: A Population Dose-response Analysis.

Chapel S, Chiu YY, Hsu J, Cucchiaro J, Loebel A.

Clin Ther. 2016 Jan 1;38(1):4-15. doi: 10.1016/j.clinthera.2015.11.013. Epub 2015 Dec 22.

9.

Population pharmacokinetics of naloxegol in a population of 1247 healthy subjects and patients.

Al-Huniti N, Chapel S, Xu H, Bui KH, Sostek M.

Br J Clin Pharmacol. 2016 Jan;81(1):89-100. doi: 10.1111/bcp.12756. Epub 2015 Oct 27.

10.

Physiologically based and population PK modeling in optimizing drug development: A predict-learn-confirm analysis.

Suri A, Chapel S, Lu C, Venkatakrishnan K.

Clin Pharmacol Ther. 2015 Sep;98(3):336-44. doi: 10.1002/cpt.155. Epub 2015 Jul 14.

11.

Comparison of QTc data analysis methods recommended by the ICH E14 guidance and exposure-response analysis: case study of a thorough QT study of asenapine.

Chapel S, Hutmacher MM, Bockbrader H, de Greef R, Lalonde RL.

Clin Pharmacol Ther. 2011 Jan;89(1):75-80. doi: 10.1038/clpt.2010.220. Epub 2010 Nov 24.

PMID:
21107314
12.

A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin.

Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P.

Clin Pharmacokinet. 2010 Oct;49(10):661-9. doi: 10.2165/11536200-000000000-00000. Review.

PMID:
20818832
13.

Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation.

Chapel S, Hutmacher MM, Haig G, Bockbrader H, de Greef R, Preskorn SH, Lalonde RL.

J Clin Pharmacol. 2009 Nov;49(11):1297-308. doi: 10.1177/0091270009344855.

PMID:
19843656
14.

A genetic strategy to control expression of human blood group antigens in red blood cells generated in vitro.

Bagnis C, Chapel S, Chiaroni J, Bailly P.

Transfusion. 2009 May;49(5):967-76. doi: 10.1111/j.1537-2995.2008.02078.x. Epub 2009 Jan 21.

PMID:
19175544
15.

Performance characteristics for some typical QT study designs under the ICH E-14 guidance.

Hutmacher MM, Chapel S, Agin MA, Fleishaker JC, Lalonde RL.

J Clin Pharmacol. 2008 Feb;48(2):215-24. doi: 10.1177/0091270007311921.

PMID:
18199896
16.

Hyperthermia enhances CTL cross-priming.

Shi H, Cao T, Connolly JE, Monnet L, Bennett L, Chapel S, Bagnis C, Mannoni P, Davoust J, Palucka AK, Banchereau J.

J Immunol. 2006 Feb 15;176(4):2134-41.

17.

Pharmacodynamics of an 800-mg dose of telithromycin in patients with community-acquired pneumonia caused by extracellular pathogens.

Lodise TP, Preston S, Bhargava V, Bryskier A, Nusrat R, Chapel S, Rangaraju M, Drusano GL.

Diagn Microbiol Infect Dis. 2005 May;52(1):45-52.

PMID:
15878442
18.

Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment.

Shi J, Chapel S, Montay G, Hardy P, Barrett JS, Sica D, Swan SK, Noveck R, Leroy B, Bhargava VO.

Int J Clin Pharmacol Ther. 2005 Mar;43(3):123-33.

PMID:
15792396
19.

Pharmacodynamic analysis of the microbiological efficacy of telithromycin in patients with community-acquired pneumonia.

Shi J, Pfister M, Jenkins SG, Chapel S, Barrett JS, Port RE, Howard D.

Clin Pharmacokinet. 2005;44(3):317-29.

PMID:
15762772
20.

Posttransfusion recovery of stored red blood cells in very low birth weight infants using a hemoglobin balance model.

Bechensteen AG, Chapel S, Veng-Pedersen P, Widness JA.

Transfusion. 2004 Jul;44(7):1019-24.

PMID:
15225242
21.

Pharmacokinetic tracer kinetics analysis of changes in erythropoietin receptor population in phlebotomy-induced anemia and bone marrow ablation.

Veng-Pedersen P, Chapel S, Al-Huniti NH, Schmidt RL, Sedars EM, Hohl RJ, Widness JA.

Biopharm Drug Dispos. 2004 May;25(4):149-56.

PMID:
15108217
22.

Pharmacoscintigraphic comparison of HMR 1031, a VLA-4 antagonist, in healthy volunteers following delivery via a nebulizer and a dry powder inhaler.

Rohatagi S, Chapel S, Kirkesseli S, Newman S, Zhang J, Paccaly D, Randall L, Wray H, Wellington S, Shah B, Jensen BK.

Am J Ther. 2004 Mar-Apr;11(2):103-13.

PMID:
14999362
23.

Pharmacokinetics and safety of the ketolide telithromycin in patients with renal impairment.

Shi J, Montay G, Chapel S, Hardy P, Barrett JS, Sack M, Marbury T, Swan SK, Vargas R, Leclerc V, Leroy B, Bhargava VO.

J Clin Pharmacol. 2004 Mar;44(3):234-44.

PMID:
14973302
24.

A differential pharmacokinetic analysis of the erythropoietin receptor population in newborn and adult sheep.

Veng-Pedersen P, Chapel S, Al-Huniti NH, Schmidt RL, Sedars EM, Hohl RJ, Widness JA.

J Pharmacol Exp Ther. 2003 Aug;306(2):532-7. Epub 2003 May 15.

PMID:
12750427
25.

An integrated pharmacodynamic analysis of erythropoietin, reticulocyte, and hemoglobin responses in acute anemia.

Veng-Pedersen P, Chapel S, Schmidt RL, Al-Huniti NH, Cook RT, Widness JA.

Pharm Res. 2002 Nov;19(11):1630-5.

PMID:
12458668
26.

Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway.

Chapel S, Veng-Pedersen P, Hohl RJ, Schmidt RL, McGuire EM, Widness JA.

J Pharmacol Exp Ther. 2001 Aug;298(2):820-4.

PMID:
11454947
27.

Receptor-based model accounts for phlebotomy-induced changes in erythropoietin pharmacokinetics.

Chapel SH, Veng-Pedersen P, Schmidt RL, Widness JA.

Exp Hematol. 2001 Apr;29(4):425-31.

PMID:
11301182
28.

Gene transfer to hepatocellular carcinoma: transduction efficacy and transgene expression kinetics by using retroviral and lentiviral vectors.

Gerolami R, Uch R, Jordier F, Chapel S, Bagnis C, Bréchot C, Mannoni P.

Cancer Gene Ther. 2000 Sep;7(9):1286-92.

29.

A pharmacodynamic analysis of erythropoietin-stimulated reticulocyte response in phlebotomized sheep.

Chapel SH, Veng-Pedersen P, Schmidt RL, Widness JA.

J Pharmacol Exp Ther. 2000 Oct;295(1):346-51.

PMID:
10992000
30.

Fate of linear and supercoiled multinucleosomic templates during transcription.

ten Heggeler-Bordier B, Schild-Poulter C, Chapel S, Wahli W.

EMBO J. 1995 Jun 1;14(11):2561-9.

31.
32.

Two functional forms of the Xenopus laevis estrogen receptor translated from a single mRNA species.

Claret FX, Chapel S, Garcés J, Tsai-Pflugfelder M, Bertholet C, Shapiro DJ, Wittek R, Wahli W.

J Biol Chem. 1994 May 13;269(19):14047-55.

33.

Intronic and 5' flanking sequences of the Drosophila beta 3 tubulin gene are essential to confer ecdysone responsiveness.

Bruhat A, Dréau D, Drake ME, Tourmente S, Chapel S, Couderc JL, Dastugue B.

Mol Cell Endocrinol. 1993 Jul;94(1):61-71.

PMID:
8375576
34.

In Drosophila Kc cells 20-OHE induction of the 60C beta3 tubulin gene expression is a primary transcriptional event.

Chapel S, Sobrier ML, Montpied P, Micard D, Bruhat A, Couderc JL, Dastugue B.

Insect Mol Biol. 1993;2(1):39-48.

PMID:
9087542
35.

Enhancer and silencer elements within the first intron mediate the transcriptional regulation of the beta 3 tubulin gene by 20-hydroxyecdysone in Drosophila Kc cells.

Tourmente S, Chapel S, Dreau D, Drake ME, Bruhat A, Couderc JL, Dastugue B.

Insect Biochem Mol Biol. 1993 Jan;23(1):137-43.

PMID:
8485515
36.

Regulatory elements in the first intron contribute to transcriptional regulation of the beta 3 tubulin gene by 20-hydroxyecdysone in Drosophila Kc cells.

Bruhat A, Tourmente S, Chapel S, Sobrier ML, Couderc JL, Dastugue B.

Nucleic Acids Res. 1990 May 25;18(10):2861-7.

37.

20-OH-ecdysone regulates 60 C beta tubulin gene expression in Kc cells and during Drosophila development.

Sobrier ML, Chapel S, Couderc JL, Micard D, Lecher P, Somme-Martin G, Dastugue B.

Exp Cell Res. 1989 Sep;184(1):241-9.

PMID:
2507336
38.

20-Hydroxyecdysone induces the expression of one beta-tubulin gene in Drosophila Kc cells.

Montpied P, Sobrier ML, Chapel S, Couderc JL, Dastugue B.

Biochim Biophys Acta. 1988 Jan 25;949(1):79-86.

PMID:
2825814
39.

Expression of a new beta tubulin subunit is induced by 20-hydroxyecdysone in Drosophila cultured cells.

Sobrier ML, Couderc JL, Chapel S, Dastugue B.

Biochem Biophys Res Commun. 1986 Jan 14;134(1):191-200.

PMID:
3080985

Supplemental Content

Loading ...
Support Center